Charlie Kirk Joins LTEN Board of Directors

By November 13, 2023November 27th, 2023Member News, NEW from LTEN


The LTEN Board of Directors has elected its newest member, Charlie Kirk of Amgen. Kirk’s term begins immediately.

Kirk is executive director, commercial training and development, rare disease for Amgen. He’s worked in life sciences sales, training and leadership since starting his career at Abbott Laboratories in 1997.  He’s also held key leadership positions with AstraZeneca, Salix Pharmaceuticals, Ironwood Pharmaceuticals, TGaS Advisors and Alkermes, before leading the commercial training organization at Horizon Therapeutics in September 2020. Horizon Therapeutics was acquired by Amgen in October 2023.

“I’m excited to take a seat on the LTEN Board of Directors,” Kirk said. “LTEN is an invaluable organization in the life sciences training industry, and it’ll be my honor to help lead, direct and guide programs designed to bring professional value to all of our members and everyone they work with, support and train.”

“Charlie is a perfect addition to the LTEN board and I know he’ll bring immediate value to our network,” said Lauren Harbert, executive director for LTEN. “He’s had strong experience in life sciences on both the industry and supplier sides, and that perspective will help us ensure LTEN meets the needs of all members.”



About LTEN

The Life Sciences Trainers & Educators Network ( is the only global 501(c)(3) nonprofit organization specializing in meeting the needs of life sciences learning professionals. LTEN shares the knowledge of industry leaders, provides insight into new technologies, offers innovative solutions and communities of practice that grow careers and organizational capabilities. Founded in 1971, LTEN has grown to more than 3,200 individual members who work in pharmaceutical, biotech, medical device and diagnostic companies, and industry partners who support the life sciences training departments.

Leave a Reply